89Zirconium-labelled girentuximab (89Zr-TLX250) PET in Urothelial Cancer Patients (ZiPUP) - A novel diagnostic and staging modality for localized and metastatic urothelial carcinoma

被引：0
|
作者：
Viswambaram, Pravin [1 ,2 ,3 ]
Al-Zubaidi, Mohammed [1 ]
McCombie, Steve [1 ,2 ,3 ]
Gauci, Richard [1 ]
Liow, Elizabeth [3 ,5 ]
Ferguson, Thomas [1 ,3 ]
Redfern, Andrew [1 ,2 ,3 ]
Lenzo, Nat [1 ,4 ,6 ]
Hayne, Dickon [1 ,2 ,3 ]
机构：
[1] Fiona Stanley Hosp, Murdoch, WA, Australia
[2] Univ Western Australia, UWA Med Sch, Crawley, Australia
[3] Australia & New Zealand Urogenital & Prostate Can, Camperdown, NSW, Australia
[4] Genesis Care, Perth, WA, Australia
[5] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[6] Curtin Univ, Dept Med, Bentley, WA, Australia
来源：
BJU INTERNATIONAL | 2022年 / 129卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：167 / 168
页数：2
相关论文
共 6 条
  • [1] 89zirconium-labelled girentuximab (89zr-tlx250) pet in urothelial cancer patients (zipup) - a phase i trial of a novel staging modality for urothelial carcinoma
    Hayne, D.
    Gauci, R.
    Hawks, C.
    Al-Zubaidi, M.
    Viswambaram, P.
    Mccombie, S.
    Liow, E. C. H.
    Lenzo, N.
    Ferguson, T.
    Martina, S.
    Hayward, C.
    Redfern, A.
    EUROPEAN UROLOGY, 2023, 83 : S744 - S745
  • [2] 89Zirconium-labelled girentuximab (89Zr-TLX250) PET in patients with urothelial cancer (ZiPUP): A phase I trial of a novel staging modality for urothelial carcinoma
    Hayne, Dickon
    Gauci, Richard
    Al-Zubaidi, Mohammed
    Viswambaram, Pravin
    McCombie, Steve P.
    Liow, Elizabeth Chien Hern
    Lenzo, Nat
    Ferguson, Thomas
    Antonini, Paola
    Meyrick, Danielle
    Hayward, Colin
    Redfern, Andrew David
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [3] 89Zirconium-labelled girentuximab (89Zr-TLX250) PET in Urothelial Cancer Patients (ZiPUP): protocol for a phase I trial of a novel staging modality for urothelial carcinoma
    Al-Zubaidi, Mohammed
    Viswambaram, Pravin
    McCombie, Steve
    Liow, Elizabeth
    Lenzo, Nat
    Ferguson, Tom
    Redfern, Andrew D.
    Gauci, Richard
    Hayne, Dickon
    BMJ OPEN, 2022, 12 (04):
  • [4] Comparison of [89Zr]Zirconium-DFO-girentuximab (89Zr-TLX250) PET/CT and PET/MRI hybrid systems in patients with suspicion of Clear Cell Renal Cell Carcinoma (ccRCC): Initial results
    Liu, Chen
    Xie, Qing
    Zhang, Yan
    Ma, Yunxia
    Liu, Shiwei
    Cerqueira, Brenda
    Brown, Tracey
    Tang, Weikun
    Du, Peng
    Yang, Zhi
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65
  • [5] Promising clinical performance of 89Zirconium-labelled Girentuximab PET-CT for imaging metastatic triple negative breast cancer patients (OPALESCENCE)
    Rousseau, Caroline
    Heymann, Marie Francoise
    Frenel, Jean Sebastien
    Picot-Dilly, Elise
    Le Thiec, Maelle
    Taupin, Manon
    Mouton, Alexis
    Bourbouloux, Emmanuelle
    Morel, Agnes
    Allam, Nadia
    Mallet, Amelie
    Campone, Mario
    Ferrer, Ludovic
    Kraeber-Bodere, Francoise
    CANCER RESEARCH, 2024, 84 (09)
  • [6] Preliminary results of a prospective pilot study, assessing imaging performance of 89Zirconium-labelled Girentuximab PET- CT in metastatic triple negative breast cancer patients
    Heymann, M. F.
    Mallet, A.
    Picot-Dilly, E.
    Le Thiec, M.
    Taupin, M.
    Mouton, A.
    Frenel, J. S.
    Bourbouloux, E.
    Allam, N.
    Ravasi, L.
    Ferrer, L.
    Kraeber-Bodere, F.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S151 - S151
1